BioCentury | Jun 16, 2020

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses. eTheRNA immunotherapies N.V. said Tuesday it raised €34...
BC Extra | Feb 27, 2019
Financial News

After J&J retinal deal, MeiraGTx raises $80M for unpartnered programs

MeiraGTx Holdings plc (NASDAQ:MGTX) added $2.23 (17%) to $15.50 on Wednesday after the company raised $80 million in a private placement, which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC Inc....
BC Extra | Jan 31, 2019
Company News

J&J, MeiraGTx partner on gene therapies for rare retinal diseases

Janssen Pharmaceuticals Inc. picked up its first clinical gene therapies Thursday in a worldwide licensing deal with MeiraGTx Holdings plc (NASDAQ:MGTX) for rare inherited retinal disease therapies. MeiraGTx added $2.84 (30%) to $12.38 on Thursday....
Items per page:
1 - 3 of 3